NeuroScientific hails 80% clinical response in Crohn’s stem cell program

NeuroScientific Biopharmaceuticals reported 80% clinical response in its StemSmart stem cell therapy for fistulising Crohn's disease, with four of five patients showing improvement and no serious adverse events recorded. All patients had setons removed and improved disease scores. The results inform the company's planned phase 2 trials beginning in Australia.

Summary by Glance · Brisbane Times